HCV Treatment
DDW 2015: Sofosbuvir/ Ledipasvir Cures Most Hepatitis C Patients with Cirrhosis
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 10 June 2015 00:00
- Written by Liz Highleyman
Sofosbuvir and ledipasvir -- the drugs in Harvoni -- are well-tolerated and highly effective for genotype 1 chronic hepatitis C patients with compensated cirrhosis, producing an overall cure rate of 96%, according to a pooled analysis of more than 500 participants in Phase 2 and 3 studies, according to a presentation at Digestive Disease Week 2015 this month in Washington, DC.
DDW 2015: Sofosbuvir + Daclatasvir for 12 Weeks Cures Most HIV/HCV Coinfected Patients
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 27 May 2015 00:00
- Written by Liz Highleyman
Nearly all HIV/HCV coinfected patients treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza) achieved sustained virological response, but the cure rate fell to 76% for those treated for only 8 weeks, according to results from the ALLY-2 trial presented at Digestive Disease Week 2015 this month in Washington, DC.
EASL 2015: Hepatitis C Treatment May Be Highly Cost-effective for Prisoners in England
- Details
- Category: HCV Treatment
- Published on Monday, 18 May 2015 00:00
- Written by Keith Alcorn, Aidsmap
Reducing the duration of direct-acting antiviral therapy for hepatitis C will make treatment for prisoners in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C treatment for people who inject drugs, Natasha Martin from the University of California San Diego reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
EASL 2015: Liver Function and Survival Improve after Hepatitis C Treatment with Viekira Pak
- Details
- Category: HCV Treatment
- Published on Wednesday, 27 May 2015 00:00
- Written by Liz Highleyman
Hepatitis C patients treated with AbbVie's Viekira Pak "3D" regimen saw improvements in liver function biomarkers, had better quality of life, and had increased survival compared to untreated people, according to mathematical model studies presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. One model showed that treatment can be cost-effective at all stages of liver disease.
Daclatasvir, Asunaprevir, and Beclabuvir Shows High Cure Rates for People with Genotype 1 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 13 May 2015 00:00
- Written by Liz Highleyman
A twice-daily fixed-dose coformulation of daclatasvir, asunaprevir, and beclabuvir taken for 12 weeks cured 91% of genotype 1 chronic hepatitis C patients without liver cirrhosis, and even higher sustained response rates were obtained for people with cirrhosis when ribavirin was added, according to findings from the Phase 3 UNITY studies published in the May 5 issue of JAMA.
More Articles...
- EASL 2015: Shortening Triple Therapy to 6 Weeks Is Effective for Some Hepatitis C Patients
- EASL 2015: Sofosbuvir/ Ledipasvir Cures More Than 90% of People with Hepatitis C Genotypes 4 and 5
- EASL 2015: Gilead Triple Combination Cures Easy-To-Treat Hepatitis C Patients in 6 Weeks
- EASL 2015: Sofosbuvir-based Therapy Effective for Hepatitis C Patients with Decompensated Cirrhosis
Web Design and Development by